The Biostatistics and Bioinformatics Core (BABC) provides statistical collaboration and data management support for each of the SPORE projects, the developmental projects, and the other Cores. In addition, the BABC also provides collaboration and support in bioinformatics and computational biology research for SPORE projects as appropriate. In the past funding period the BABC established the infrastructure to link the Lymphoma clinical and research databases between Ul and MC. This system is fully functional and allows web-based registration and data entry from both sites into a common database. The BABC developed the statistical plan for the 4 clinical trials (LS0388, LS0382, LS038B, LS058C) initiated in the SPORE as well as the SPORE imaging trial (LS0383). This core provides data management for each of these trials, monitors adverse events in collaboration with the Clinical Research Core, and prepares data summaries for manuscript preparation. The BABC has been very active in preparing the statistical plan for each of the four Projects in this competitive renewal. Each of the projects presented in this application reflects input from members of the BABC on study design, analysis plan, and bioinformatics needs. These projects span a wide range of approaches and analyses required. The BABC builds upon the innovative and time-tested procedures and systems developed by Mayo Clinic, one of the largest statistical groups in the country whose members have collaborated on more than 8,000 clinical and basic science research studies since 1966, as well as the Coordinated Laboratory for Computational Genomics at the University of Iowa founded in 1996. The BABC will provide statistical and bioinformatics support across different fields, including epidemiological studies, basic sciences including translational and immunologic correlative studies, gene microarray and imaging, clinical trials, and gene and mutation discovery, expression analysis and genomics, and information management. The comprehensive nature of the BABC, which will have activities at both the MC and Ul, assures each SPORE investigator access to statistical and bioinformatics expertise that includes collaborative development of study designs and analysis plans, state of the art data analysis and interpretation, data management resources, and abstract and manuscript preparation. The BABC also provides a mechanism for the management and integration of both existing and newly collected data through consistent and compatible data handling. Areas of support include database development, data form development and processing, data collection and entry, data archiving, quality control, and management of information relating to gene mutation identification and genotyping data for disease linkage experiments. This Core complements and assists the efforts of the Clinical Research and Biospecimens Cores by providing superior data management and experience with tissue registries. The strengths of the BABC are our collaboration with each of the projects and cores, the ability to utilize the established centralized research database as well as the operational and statistical infrastructure already in place in the UI/MC Lymphoma SPORE, and the breadth of expertise provided by BABC personnel.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097274-09
Application #
8076895
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
9
Fiscal Year
2010
Total Cost
$168,328
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Thanarajasingam, Gita; Maurer, Matthew J; Farooq, Umar et al. (2018) Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 183:149-152
Kleinstern, Geffen; Maurer, Matthew J; Liebow, Mark et al. (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73
Saad Aldin, Ehab; McNeely, Parren; Menda, Yusuf (2018) Posterior Reversible Encephalopathy Syndrome on 18F-FDG PET/CT in a Pediatric Patient With Burkitt's Lymphoma. Clin Nucl Med 43:195-198
Link, Brian K; Day, Bann-Mo; Zhou, Xiaolei et al. (2018) Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol :
Ebeid, Kareem; Meng, Xiangbing; Thiel, Kristina W et al. (2018) Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol 13:72-81
Holahan, Heather M; Farah, Ronda S; Fitz, Sara et al. (2018) Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol 57:1314-1319
Maurer, Matthew J; Ghesquières, Hervé; Link, Brian K et al. (2018) Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol 36:1603-1610
Huet, Sarah; Tesson, Bruno; Jais, Jean-Philippe et al. (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Mackrides, Nicholas; Chapman, Jennifer; Larson, Melissa C et al. (2018) Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. Am J Hematol :

Showing the most recent 10 out of 387 publications